(Q24241156)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19160327%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

0 references

1 reference

title

Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19160327%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19160327%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Felix Ratjen

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19160327%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Anne Stephenson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19160327%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Elizabeth Tullis

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19160327%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

21 January 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19160327%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

20 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19160327%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19160327%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

CD007168

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19160327%20AND%20SRC:MED&resulttype=core&format=json

A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

Acute effects of aerosolized S-nitrosoglutathione in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

Prevention of tissue damage: inhibition of myeloperoxidase mediated inactivation of alpha 1-proteinase inhibitor by N-acetyl cysteine, glutathione, and methionine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

Determinants of mortality from cystic fibrosis in Canada, 1970-1989.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

Cystic fibrosis since 1938.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

MUC5AC and MUC5B Mucins Are Decreased in Cystic Fibrosis Airway Secretions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

Mucolytics in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

Current concepts of redox signaling in the lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

Nebulised hypertonic saline for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

Immediate effect of various treatments on lung function in infants with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

7 January 2021

A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

7 January 2021

Variance imputation for overviews of clinical trials with continuous response

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

7 January 2021

Bronchial drainage with aerosol medications in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

7 January 2021

Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

7 January 2021

The Management of Cystic Fibrosis with Carbocysteine Lysine Salt: Single-Blind Comparative Study with Ambroxol Hydrochloride

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007168.PUB2

7 January 2021

10.1002/14651858.CD007168.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19160327%20AND%20SRC:MED&resulttype=core&format=json

release_symeubgcfrfylbwsbvmcgpmwq4

20 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/symeubgcfrfylbwsbvmcgpmwq4

24 November 2022

mapped directly with Wikidata item

1 reference